News | February 23, 2026
Bavarian Nordic bags $22.5M Canadian vaccine order
The order will cover the manufacturing of bulk vaccine in 2026
The order will cover the manufacturing of bulk vaccine in 2026
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
The data highlights its RSV vaccine cuts hospitalizations in older adults
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
The VELO system supports multiplex testing for Influenza A, Influenza B, and COVID-19, producing PCR results in six to ten minutes
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
Duvakitug was well tolerated and safety was consistent with the induction study
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Subscribe To Our Newsletter & Stay Updated
